GoldenGolden
Compass Therapeutics

Compass Therapeutics

Compass Therapeutics is an antibody Therapies.

Compass Therapeutics develops antibody therapeutics that target the immune synapse for treatment of cancer. The immune synapse is the term for the molecular interactions which are part of an immune response which takes place in the gap between T cells and antigen presenting cells. Proper regulation ensures a balance where the host defends against pathogens and tumors and also does not develop autoimmunity. Compass Therapeutics is developing antibodies that engage T cells, NK cells and macrophages to promote tumor-specific activation or reverse immune suppression.

The company’s lead candidate as of 2020 was CTX-471, a fully human agonistic antibody of CD137 in clinical Phase 1 studies in patients with advanced solid tumors. Compass’s CTX-8371 drug in development is a novel PD-1/PD-L1 bispecific antibody.

Timeline

People

Name
Role
LinkedIn

Thomas Schuetz, M.D., Ph.D

Co-Founder, CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
May 14, 2021
FierceBiotech
Compass Therapeutics has struck a deal to acquire a clinical-phase bispecific antibody. The deal will see Compass buy Trigr Therapeutics for a DLL4xVEGF-A candidate that is being studied in patients with solid tumors.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.